As mentioned above, it is evident that PSA-based screening results in reduction in prostate cancer-specific mortality, but it is associated with harm related to subsequent evaluation and treatments, some of which may be unnecessary [11, 18]. This evidence concerns the gene KLK3 and prostate carcinoma.